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Objective In the Republic of Korea (ROK), soldiers stationed where there is a risk of contracting malaria have received antimalarial 
chemoprophylaxis since 1997. However, chemoprophylaxis may facilitate the development of drug resistance, and late primary 
attacks in individuals who have received chemoprophylaxis are becoming more frequent. We investigated the association between 
chemoprophylaxis and the epidemiological characteristics and effectiveness of treatment for re-emergent Plasmodium vivax malaria, 
using a nationwide malaria database.
Methods Among soldiers at risk of malaria between 1999 and 2001, we reviewed all P. vivax malaria cases (1158) that occurred 
before 31 December 2003. Early and late primary attacks were defined as cases occurring < 2 or > 2 months after the last day of 
exposure to risk of malaria, respectively.
Findings Of these cases, 634 (72.0%) had received chemoprophylaxis, and 324 (28.0%) had not. Cases occurred mostly in summer, 
with a peak in July–August. Stratification by chemoprophylaxis history revealed different times to onset. Early primary attacks were more 
prevalent in the group not receiving chemoprophylaxis, while in the group receiving chemoprophylaxis most cases were late primary 
attacks. Of the latter, 312 out of 461 (67.7%) did not take primaquine regularly. After treatment of the first attack, 14 (1.2%) of 1158 
were re-treated; all re-treated cases were cured using the same doses and regimen used for the first treatment.
Conclusion In ROK, the increase in late primary episodes of re-emergent P. vivax malaria is associated with the use of antimalarial 
chemoprophylaxis.
Bulletin of the World Health Organization 2006;84:827-834.
Voir page 833 le résumé en français. En la página 833 figura un resumen en español.
Introduction
Plasmodium vivax, the causative agent 
of vivax malaria, has been endemic in 
the Republic of Korea (ROK) for cent
turies. The number of cases of endemic 
malaria began to decline in the 1960s, 
partly due to increased socioeconomic 
development, increased use of agricult
tural pesticides, and the efforts of the 
National Malaria Eradication Service. 
These factors contributed to the eradicat
tion of malaria in the ROK, resulting in 
the declaration by WHO in 1979 that 
the country was malariatfree.1 In 1993, 
one case of malaria attributed to autot
chthonous transmission was detected 
near the demilitarized zone (DMZ) 
that separates ROK (south) from the 
Democratic People’s Republic of Korea 
(north).2 Since 1993, the number of 
malaria cases has increased exponentially, 
particularly among soldiers based near 
the DMZ.1–5
Chemoprophylaxis and the epidemiological characteristics 
of re-emergent P. vivax malaria in the Republic of Korea
Changsoo Kim,a Dong Chun Shin,a Tai Soon Yong,b Dae Kyu Oh,c Rock Kwon Kim,d Keeho Park,c & Il Suh a
.833 ةحفص في ةيبرعلاب صخللما لىع علاطلاا نكيم
a  Department of Preventive Medicine, Yonsei University College of Medicine, 134 Shinchon-Dong, Seodaemun-Gu, Seoul 120-752, Seoul, Republic of Korea. 
Correspondence to Il Suh (email: isuh@yumc.yonsei.ac.kr).
b  Department of Parasitology, Yonsei University College of Medicine, Seoul, Republic of Korea.
c  Korea Center for Disease Control and Prevention, Seoul, Republic of Korea.
d  The Armed Forces Medical Command, Seoul, Republic of Korea.
Ref No. 05-029546
(Submitted: 29 December 2005 – Final revised version received: 3 April 2006 – Accepted: 18 April 2006)
In ROK, healthy males aged over 
18 years serve 26 months of mandat
tory military duty; most are stationed 
throughout their service near the DMZ, 
where the risk of malaria is highest. 
After finishing their military duty, the 
soldiers return from these risk areas to 
areas with little or no malaria. To reduce 
the occurrence of malaria among curt
rent and former soldiers, the military 
initiated antimalarial chemoprophylaxis 
in 1997.
Although chemoprophylaxis ret
duces the number of cases of malaria, 
longtterm chemoprophylaxis can fat
cilitate the development of drug resist
tance.6,7 Recently, although there have 
been no reports of treatment failure in 
ROK, an increase in late primary epit
sodes of P. vivax malaria among soldiers 
who had received chemoprophylaxis 
has raised doubts regarding its effectivet
ness. A recent study in ROK showed 
that prophylaxis with primaquine was 
not effective in preventing late primary 
attacks.8
We investigated the association 
between chemoprophylaxis and the 
epidemiological characteristics and eft
fectiveness of treatment for retemergent 
P. vivax malaria, using a nationwide 
malaria database.
Methods
Chemoprophylaxis
Chemoprophylaxis with hydroxychlorot
quine sulfate (400 mg, once per week) is 
started in early summer and continued 
throughout the transmission season. 
Fourteentday prophylaxis with primat
quine (15 mg of base, once per day) is 
started on the first day of the last week 
of chloroquine administration. During 
military duty, soldiers assigned to areas 
at risk of malaria experience two cont
secutive transmission seasons and ret
ceive chemoprophylaxis each season. In 
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addition to chemoprophylaxis, in 1998 
the military adopted the use of permet
thrinttreated battletdress uniforms and 
bednets, and the application of mosquito 
vectortcontrol agents. The number of 
soldiers receiving chemoprophylaxis and 
the amount of permethrin used have 
increased annually (Table 1).
Malaria surveillance
In ROK, malaria cases in soldiers must 
be reported to the Armed Forces Medit
cal Command, and cases in veterans and 
civilians must be reported to the Korea 
Center for Disease Control and Prevent
tion.4,9 Malaria cases in veterans are 
defined as those experiencing a malaria 
attack within 24 months after retiret
ment. Soldiers diagnosed with malaria 
are admitted to a military hospital for 
treatment and are interviewed by physit
cians; veterans are treated in community 
outpatient clinics and are interviewed by 
trained publicthealth specialists. All solt
diers and veterans diagnosed with P. vivax 
malaria receive standard treatment: 2 g of 
hydroxychloroquine sulfate (1200, 400, 
and 400 mg on days 1 to 3, respectively) 
and 210 mg of primaquine (15 mg of 
base, once per day for 14 days).
Study subjects
We reviewed all cases of P. vivax malaria 
reported to the Armed Forces Medical 
Command and Korea Center for Disease 
Control and Prevention that occurred 
before 31 December 2003 in soldiers 
who had entered the ROK army during 
nontrisk periods between 1 October 
1998 and 28 February 2001 and who 
had been exposed to risk of malaria for 
the first time in military service between 
1999 and 2001. We defined the malaria 
risk period as 1 May to 30 September. 
Cases in soldiers who had entered the 
ROK army between 1 March and 30 
Table 1. Antimalarial chemoprophylaxis and insecticide-treated materialsa received by soldiers in the Republic of Korea army
Precaution Year
1999 2000 2001 2002
Chemoprophylaxis (No. of soldiers) 61 772 90 000 109 476 141 780
Period of chemoprophylaxis:
Chloroquineb 7 June–11 October 5 June–9 October 14 May–24 September 13 May–23 September
Primaquinec 12–25 October 3–16 October 18 September–1 October 17–30 September
Insecticide-treated materialsa  
(No. of soldiers)
80 000 80 000 150 692 157 361
a  Permethrin (6.4 g per person for 3 months) was used to treat battle-dress uniforms and bednets.
b  Hydroxychloroquine sulfate at a weekly dose of 400 mg.
c  Primaquine base at a daily dose of 15 mg.
April (who would retire during a malaria 
risk period) or who retired during a mat
laria risk period were excluded because 
we could not discriminate between early 
(individuals infected in the year of retiret
ment) and late (individuals infected in 
the year before retirement) primary att
tacks. Therefore, the subjects exposed to 
risk of malaria for the first time between 
1999 and 2001 were those who had 
entered military service between the bet
ginning of October 1998, 1999, or 2000 
and the end of the respective following 
February 1999, 2000 or 2001.
During the study period, 1215 cases 
of P. vivax malaria were reported. Of 
these, 56 in soldiers who had been in 
malaria risk areas after retirement (46 
received chemoprophylaxis during milit
tary duty and 10 did not) and one case 
from Africa were excluded. Ultimately, 
1158 cases were analysed.
Statistical analysis
Cohorts of individuals exposed to risk 
of malaria in each year between 1999 
and 2001 were constructed. Early and 
late primary attacks were defined as 
cases occurring < 2 or > 2 months after 
the last day of the malaria risk period, 
respectively. 
This study included all cases that 
occurred among defined populations; 
we therefore fixed the denominator in 
the chemoprophylaxis and notchemot
prophylaxis groups such that the cases 
represent the epidemiological charactert
istics of P. vivax malaria in each group. 
To analyse the proportional difference in 
early and late primary attacks between 
the groups that did or did not receive 
chemoprophylaxis, we divided the 1158 
cases into two groups according to the 
timing of symptom onset (“before” and 
“after” the second round of chemoprot
phylaxis began) because the number 
of soldiers receiving chemoprophylaxis 
changed each year. All cases that were 
primary attacks were followed until 31 
December 2003 after treating the first 
attack.
Ethical issues
This study was approved by the Ethical 
and Security Committee for clinical 
research at Office of Surgeon General, 
Army Headquarters, Gyeryong, Republic 
of Korea.
Table 2. Cases of P. vivax malaria in soldiers and veterans of the Republic of Korea 
army, by exposure cohort
First year of 
exposure
No. of 
patientsa
Onset of symptomsb
First yearc Second yeara Third yeara
1999 590 (209) 28 351 (2) 211 (207)
2000 370 (138) 30 201 139 (138)
2001  198  (80) 10 106 82 (80)
Total    1158 (427) 68 657 (2) 432 (425)
a  Figures in parentheses are numbers of cases that occurred after retirement.
b  In the first and second year of follow-up, all cases were among soldiers exposed to risk of malaria; in 
the third year of follow-up, no cases were exposed to risk of malaria.
c  Cases that occurred in the first year of exposure.
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Results
Of the 1158 cases, 634 (72.0%) had ret
ceived chemoprophylaxis during military 
duty, and 324 (28.0%) had not. All cases 
were among soldiers stationed in malaria 
risk areas during military duty.
The year of symptom onset for each 
exposure cohort is shown in Table 2. 
Most cases occurred in summer (May–
August), with a peak in July–August. 
In winter (December–February), only 
12 cases (4, 7, and 1 in the first, second 
and third winters, respectively) occurred 
(Fig. 1). To investigate the monthly 
distribution of early and late primary 
attacks by history of chemoprophylaxis, 
we analysed the cases that occurred in the 
first and third years; cases that occurred 
in the second year were excluded in the 
analysis because early and late primary 
attacks occurred concurrently. Of the 
cases (mostly early primary attacks) that 
occurred in the first year, numbers in 
the notchemoprophylaxis group peaked 
before those in the chemoprophylaxis 
group, while the monthly distribution of 
cases (late primary attacks) that occurred 
in the third year was similar in the two 
groups (Fig. 2).
Of the 1158 cases, 195 (16.8%) 
occurred before, and 963 (83.2%) after 
the second round of chemoprophylaxis 
started. Stratification of the cases on the 
basis of history of chemoprophylaxis 
revealed different times to onset (Fig. 3). 
The number of malaria cases in the 
notchemoprophylaxis group increased 
within 5 months of first exposure to mat
laria risk, as seen in Fig. 3a (72.2%) and 
Fig. 3b (77.3%). In the group receiving 
chemoprophylaxis, however, most cases 
occurred after 10 months, as seen in Fig. 
3a (84.6%) and Fig. 3b (58.2%).
Of the 195 cases that occurred 
before the start of the second round 
of chemoprophylaxis, 107 (87.0%) of 
the 123 cases in the group receiving 
chemoprophylaxis and 20 (27.8%) of 
the 72 cases that did not receive chemot
prophylaxis were late primary attacks 
(Table 3). All the cases in the group 
receiving chemoprophylaxis received 
chloroquine, and 44 (41.1%) of the 
107 cases that were late primary attacks 
finished prophylaxis with primaquine. 
Of the 963 cases that occurred after the 
second round started, 354 (59.2%) of 
the 598 cases in the group receiving 
chemoprophylaxis and 79 (21.6%) 
of the 365 cases who did not receive 
the second chemoprophylaxis were 
late primary attacks. Of the 354 cases 
that were late primary attacks and who 
received the second chemoprophylaxis, 
105 (29.7%) completed prophylaxis 
with primaquine.
After using the history of first chet
moprophylaxis to stratify the 963 cases 
that occurred after the start of the second 
round, the proportion of late primary 
attacks was found to be significantly 
higher among cases who received the 
second chemoprophylaxis than among 
those who did not, regardless of first 
chemoprophylaxis history (Table 4, web 
version only, available from: http://www.
who.int/bulletin).
After the first attack had been 
treated, 14 (1.2%) out of 1158 cases 
were rettreated for P. vivax malaria. All 
the first attacks occurred during military 
duty; in seven cases, a second attack oct
curred after retirement. A third episode 
of P. vivax malaria occurred in one case 
within 1 month after the second attack 
during military duty. After excluding 
Fig. 1. Monthly distribution for cases of P. vivax malaria in soldiers and veterans 
of the army of the Republic of Korea, for each exposure cohort
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the cases that occurred in 2003 (relapses 
would have occurred in 2004 or later), 
484 out of 1076 cases were not exposed to 
risk of malaria after the first diagnosis. Of 
the 484 cases, 2 (0.4%) were rettreated as 
P. vivax malaria > 6 months (204 and 351 
days) after the first attack. All rettreated 
cases were cured using the same doses and 
regimen used for the first treatment.
Discussion
Early primary attacks are usually defined 
as cases occurring < 1 month after 
exposure 10,11; however, to investigate 
the epidemiological characteristics of 
retemergent P. vivax malaria, we det
fined early onset as cases occurring < 2 
months after the last day of the malaria 
risk period (before December). Cases 
that occurred in the first year (i.e. cases 
infected in the first year) and third year 
(i.e. cases with infections from the pret
vious year) showed a typical unimodal 
peak in summer, regardless of the history 
of chemoprophylaxis, and only a few 
cases occurred in winter (Fig. 2). Thus 
it is obvious that early primary attacks 
occurred before winter. The cases that 
occurred in November might have been 
caused by infection in late September or 
early October; therefore, we categorized 
all the cases that occurred in November 
as early primary attacks.
In this study, most cases occurred 
in summer, with a peak in July–August, 
and the monthly distribution paralleled 
the density of the mosquito populat
tion.12 After stratification by history 
of chemoprophylaxis, symptom onset 
in cases occurring in the first year was 
delayed in the group receiving chemot
prophylaxis compared with that in the 
notchemoprophylaxis group, while it 
was similar in both groups for the cases 
that occurred in the third year. This sugt
gests that bloodtstage schizonticide (by 
chloroquine) is associated with delayed 
symptom onset and that the latency pet
riod of late primary attack is not related 
to chemoprophylaxis.
Studies conducted between about 
1950 and the 1970s demonstrated that 
Korean P. vivax malaria had both short 
and long latency periods and that most 
cases had a long latency, characteristic of 
P. vivax malaria in temperate regions.13–15 
A recent study also suggested that twot
thirds of retemergent cases of P. vivax 
malaria had a long latency, with a mean 
duration of 10 months, although longt
latency forms of P. vivax malaria might 
have been overrepresented because only 
cases that occurred after retirement were 
included.16 Unlike previous studies, most 
cases in this study involving soldiers and 
veterans that did not receive chemot
prophylaxis were early primary attacks, 
while most cases that received chemot
prophylaxis were late primary attacks. 
These findings suggest that retemergent 
P. vivax malaria has epidemiological 
characteristics that differ from those of 
the P. vivax malaria that was in existence 
between about 1950 and the 1970s, 
but that are similar to those of tropical 
strains, which have a short latency period 
before symptom onset.13 Moreover, the 
use of antimalarial chemoprophylaxis 
can change the pattern of malaria oct
currence. Although genetic evidence 
suggests that retemergent P. vivax has a 
Chinese or Democratic People’s Republic 
of Korean origin,17,18 genetic variation 
might have arisen in response to chemot
prophylaxis or climate change. A recent 
study demonstrated that the merozoite 
surface protein (MSP) gene nucleotide 
sequence of P. vivax in ROK is similar 
to that of Thai isolates.19 However, we 
can not conclude that our results show 
evidence of tropical strains in ROK 
because strain characterization was not 
performed. To identify the biological 
characteristics and origin of retemergent 
P. vivax malaria, further molecular epit
demiological analysis is needed.
Fig. 2. Monthly distribution of cases of P. vivax malaria during the first and third 
years of follow-up in soldiers and veterans of the army of the Republic of 
Korea
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Most late primary attacks (312 of 
461 cases, or 67.7%) in the group receivt
ing chemoprophylaxis were in soldiers 
who had not taken primaquine prophyt
laxis regularly, implicating nontadhert
ence to prophylaxis as a major cause of 
the increase in late primary attacks. Two 
additional factors might have affected 
the observed increase in late primary 
attacks among those who had received 
chemoprophylaxis.
First, primaquine may not effect
tively reduce late primary attacks; a 
recent study in ROK reported that the 
effectiveness of primaquine prophylaxis 
against late primary attacks was 32%,8 
and that the doses of primaquine used 
in ROK would be considered inadequate 
in other countries.20–24 In this study, late 
primary attacks occurred in individuals 
who had received primaquine prophyt
laxis regularly, and it is thus possible that 
factors such as inadequate primaquine 
dosage and absorption are associated 
with P. vivax malaria. However, only 
0.4% of those receiving the standard 
prophylactic dose of primaquine were 
rettreated for relapse, suggesting that 
primaquine effectively reduces the incit
dence of late primary attacks.
Second, symptom onset might 
be masked in patients receiving chet
moprophylaxis because of bloodtstage 
schizonticidal activity; consequently, the 
number of late primary attacks might 
increase. This hypothesis is supported 
by two findings: (1) the stratification 
of cases by history of chemoprophyt
laxis revealed delayed symptom onset 
in early primary attacks and a different 
proportion in late primary attacks; and 
(2) 32.3% of late primary attacks in the 
group receiving chemoprophylaxis were 
in men who had taken chloroquine and 
primaquine. Interestingly, in this study, 
cases of delayed symptom onset did 
not occur immediately after the end of 
chloroquine prophylaxis and convert 
into late primary attacks. Owing to det
sign limitations, we could not find any 
determinants associated with the latency 
of P. vivax malaria, and further investigat
tions are needed.
For these two reasons, the increase 
in late primary attacks in the group ret
ceiving chemoprophylaxis may be largely 
associated with patient nontadherence 
to primaquine and a delay in symptom 
onset attributable to chemoprophyt
laxis. These findings are important not 
only for planning chemoprophylaxis 
Fig. 3. Cumulative percentage of P. vivax malaria cases that occurred before and 
after the start of the second round of chemoprophylaxis
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programmes for areas with little or no 
malaria risk, because late primary attacks 
can directly affect the spread of malaria, 
but also for assessing the effectiveness of 
prophylaxis with primaquine, because 
chloroquine is a powerful potential 
confounding factor.25 If the effects of 
chloroquine are not considered, the eft
ficacy of prophylaxis with primaquine 
could be significantly underestimated 
owing to symptom onset delay.8
Primaquine is the only available 
drug that eliminates livertstage parat
sites, although other drugs such as 
tafenoquine and malarone are being 
tested.20,26,27 Primaquine is a longtterm 
medication (usually 14 days), and low 
compliance can be a problem.28 To 
increase compliance, the ROK military 
requires that all soldiers take antimalarial 
drugs under direct supervision and sign 
a drug administration checklist. In adt
dition, to reduce late primary attacks 
occurring after retirement, all soldiers 
who were stationed in risk areas and 
retiring during the malaria risk period 
receive primaquine prophylaxis before 
retirement. Nevertheless, for a variety 
of reasons, low compliance with chet
moprophylaxis remains a major problem 
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in ROK. In this study, most of those 
who had late primary attacks had not 
taken primaquine regularly. Thus, to 
effectively reduce malaria among soldiers 
and veterans, a continuing education 
programme and strict compliance with 
chemoprophylaxis are essential.
Some studies have suggested that, 
because mass antimalarial chemoprot
phylaxis in endemic areas dose not ret
duce malaria transmission, other prevent
tive measures such as insecticidettreated 
battle dress uniforms and bednets, and 
residual spraying are critical for controlt
ling transmission.6,7,29 The situation in 
ROK is unusual because sporozoitet
infected mosquitoes moving from north 
to south across the DMZ caused the 
retemergence of malaria.30,31 Although 
malaria has spread south of the DMZ, 
most cases still occur near the DMZ.32 
Moreover, a state of military confrontat
tion still exists along the DMZ. For these 
reasons, the goals of chemoprophylaxis 
in the ROK military are to reduce the 
number of malaria cases and to limit the 
spread of malaria into nontrisk areas. On 
the basis of our results, it is impossible 
to determine whether chemoprophylaxis 
should be encouraged or discouraged 
to reduce the number of late primary 
attacks. If chemoprophylaxis were to 
be discontinued, the number of late 
primary attacks would increase with the 
total number of malaria cases. Cont
versely, although no report on treatment 
failure has been issued, the continuation 
of longtterm chemoprophylaxis might 
enhance resistance or tolerance to ant
timalarial drugs. Given that most cases 
occurring during April and May are late 
primary attacks from the previous year, 
chemoprophylaxis and other prevention 
measures should be started at the begint
ning of April to reduce the potential for 
transmission to humans. However, the 
best way to control P. vivax malaria in 
the Korean peninsula is to ensure that 
malaria eradication programmes are 
performed in the Democratic People’s 
Republic of Korea and in ROK. Although 
the ROK Government has supported 
malariatprevention programmes in the 
Democratic People’s Republic of Korea 
since 2001, and in 2005 provided the 
equivalent of US$ 877 000 of malariat
related aid and equipment via WHO,33 
support for aid programmes must be 
continued and extended.
Our study has several limitations. 
First, misclassification bias could be a 
major limitation. Both early and late 
primary attacks occurred concurrently 
during the malaria risk period in the 
second year, and the secondtyear cases 
were categorized as early or late accordt
ing to the timing of symptom onset. 
However, many of the cases that oct
curred between May and early June 
(before chemoprophylaxis started) in the 
second year might actually have been late 
primary attacks in individuals infected in 
the first year, given that only two cases 
occurred between May and June in the 
first year. Considering the cases that oct
curred before the second round of chet
moprophylaxis and excluding 87 cases 
(76 in the chemoprophylaxis group; 
11 in the notchemoprophylaxis group) 
that occurred after 1 May in the second 
year, the proportion of late primary att
tacks was also significantly higher in the 
chemoprophylaxis group (66.0% versus 
14.8%). It was impossible to distinguish 
early and late primary attacks during 
and after the malaria risk period in the 
second year. However, among the cases 
presenting before the second round of 
chemoprophylaxis, late primary attacks 
were more prevalent in the group receivt
ing chemoprophylaxis, suggesting that the 
proportional difference between the chet
moprophylaxis and notchemoprophylaxis 
groups in late primary attacks occurring 
after the start of the second round can be 
considered to be a conservative estimate, 
and thus it appears that our results are not 
greatly affected by misclassification bias.
The second limitation is that the 
number of late primary attacks might 
have been overtestimated because gamet
tocytetbearing subjects can reintroduce 
malaria to mosquitoes outside the risk 
area. However, the number of secondary 
and tertiary transmitted cases was probt
ably small and is unlikely to have affected 
our results, because no cases among 
soldiers and few civilian cases (23 out 
of 609 cases in 2003) were reported in 
nontrisk areas during the study period, 
and most of those cases had a history of 
travel to malaria risk areas.5
Conclusions
Despite its limitations, our study demont
strates that retemergent P. vivax malaria in 
ROK shows epidemiological characterist
tics that differ from those of the P. vivax 
malaria that existed between about 1950 
and the 1970s, and that the increase in late 
primary episodes of retemergent P. vivax 
malaria is significantly associated with the 
use of antimalarial chemoprophylaxis. 
Although no treatment failures have been 
reported in ROK, further investigations of 
malariatprevention strategies are needed to 
ensure control of late primary episodes of 
P. vivax malaria and to prevent the det
velopment of resistance or tolerance to 
antimalarial drugs.  O
Acknowledgments
We thank Terry A Klein, Minh C Hoang, 
Youngkeun Kim, and Donghoon Ko for 
their comments on an early version of 
the manuscript.
Competing interests: none declared.
Table 3. Cases of P. vivax malaria that occurred before or after the start of the 
second round of chemoprophylaxis in soldiers and veterans of the 
Republic of Korea army
Chemoprophylaxis No. of 
patients
Latency period P-valuea
Early Late
Beforeb Yes  123  (100)c 16 (13.0) 107 (87.0) < 0.001
No  72  (100) 52 (72.2) 20 (27.8)
Total 195 (100) 68 (34.9) 127 (65.1)
Afterd Yes 598 (100) 244 (40.8) 354 (59.2) < 0.001
No 365 (100) 286 (78.4) 79 (21.6)
Total 963 (100) 530 (55.0) 433 (45.0)
a  c² test.
b  History of first chemoprophylaxis.
c  Figures in parentheses are percentages.
d  History of second chemoprophylaxis.
833Bulletin of the World Health Organization | October 2006, 84 (10)
Research
Chemoprophylaxis and re-emergent P. vivax malaria in the Republic of Korea Changsoo Kim et al.
Résumé
Chimioprophylaxie et caractéristiques épidémiologiques du paludisme à P. vivax réémergent en 
République de Corée
Objectif En République de Corée, les soldats stationnés dans 
des zones où ils étaient exposés à un risque de contracter le 
paludisme reçoivent une chimioprophylaxie antipalustre depuis 
1997. Cependant, ce traitement peut faciliter le développement 
d’une pharmacorésistance et les accès primaires tardifs deviennent 
de plus en plus fréquents chez les individus l’ayant reçu. On a 
étudié les possibilités d’associations entre cette chimioprophylaxie 
d’une part et les caractéristiques épidémiologiques du paludisme à 
Plasmodium vivax réémergent et l’efficacité du traitement d’autre 
part en utilisant une base de données mondiale sur le paludisme.
Méthodes Parmi les soldats exposés à un risque de paludisme 
entre 1999 et 2000, on a étudié tous les cas de paludisme à P. 
Vivax (1158) apparus avant le 31 décembre 2003. Les accès 
précoces et tardifs ont été définis respectivement comme les cas 
survenant dans un délai < 2 mois ou > 2 mois après le dernier 
jour d’exposition au risque de paludisme.
Résultats Parmi ces cas, 634 (72,0 %) avaient reçu une 
chimioprophylaxie antipalustre et 324 (28,0 %) non. Les cas de 
paludisme sont apparus principalement en été, avec un pic en 
juillet-août. La stratification par antécédents de chimioprophylaxie 
a fait apparaître des différences dans les délais d’apparition. Une 
plus forte prévalence des accès précoces a été relevé dans le groupe 
n’ayant pas reçu de chimioprophylaxie, tandis que dans le groupe 
traité, la plupart des cas correspondaient à des accès primaires 
tardifs. Parmi ces derniers, 312 parmi 461 (67,7 %) ne prenaient 
pas régulièrement leur primaquine. Après le traitement du premier 
accès, 14 individus (1,2 %) parmi 1158 ont dû être retraités ; tous 
les cas retraités ont été guéris en utilisant la même posologie et le 
même schéma thérapeutique que pour le premier traitement.
Conclusion En République de Corée, il existe une association entre 
l’augmentation des cas d’accès primaires de paludisme à P. Vivax 
réémergent et l’utilisation d’une chimioprophylaxie antipalustre.
Resumen
Quimioprofilaxis y epidemiología de la malaria reemergente por P. vivax en la República de Corea
Objetivo En la República de Corea, los soldados emplazados en zonas 
con riesgo de malaria vienen recibiendo quimioprofilaxis antimalárica 
desde 1997. Sin embargo, la quimioprofilaxis puede facilitar la 
aparición de farmacorresistencia, y la observación de ataques 
primarios tardíos en personas que han recibido quimioprofilaxis es 
cada vez más frecuente. Investigamos la relación existente entre la 
quimioprofilaxis y las características epidemiológicas y la eficacia del 
tratamiento de la malaria reemergente por Plasmodium vivax, usando 
para ello una base de datos de ámbito nacional sobre la malaria.
Métodos Entre los soldados expuestos al riesgo de contraer 
malaria entre 1999 y 2001, estudiamos todos los casos de malaria 
por P. vivax (1158) registrados antes del 31 de diciembre de 
2003. Se definieron como ataques primarios tempranos o tardíos 
los casos ocurridos < 2 o > 2  meses después del último día de 
exposición al riesgo de malaria, respectivamente.
Resultados De esos casos, 634 (72,0%) habían recibido 
quimioprofilaxis, y 324 (28,0%) no. Los casos se produjeron sobre 
todo en verano, con un máximo en julio/agosto. La estratificación 
en función de los antecedentes de quimioprofilaxis reveló distintos 
intervalos de incubación de la enfermedad. Los ataques primarios 
tempranos fueron más frecuentes en el grupo no sometido a 
quimioprofilaxis, mientras que en el grupo sometido a ella la mayoría 
de los casos fueron ataques primarios tardíos. De estos últimos, 312 
de 461 (67,7%) no tomaban primaquina de forma regular. Tras el 
tratamiento del primer ataque, 14 (1,2%) de 1158 casos fueron 
tratados de nuevo; todos los casos retratados se curaron con las 
mismas dosis y pautas usadas en el primer tratamiento.
Conclusiones En la República de Corea, el aumento de ataques 
primarios tardíos de malaria reemergente por P. vivax aparece 
asociado a la quimioprofilaxis antimalárica.
صخلم
ايروك ةيروهمج في ةطيشنلا تاروصتلما نع ةمجانلا ديدج نم ةثعبنلما ايرلاملل ةيئابولا صئاصخلاو ةيئايميكلا ةياقولا
 ىودعلا  رطخ اهدوسي  قطانم  في  نوركسعي  نيذلا  دونجلا  ى َّقلتي  :فدهلا
 لاإ ؛1997 ماع ذنم ايرلالما نم ةيئايميكلا ةياقولا ايروك ةيروهمج في ايرلالماب
 دايزلا يدؤي مام ةيودلأل ةمواقلما ثودح نم لهست دق ةيئايميكلا ةجلاعلما نأ
 .ةيئايميك ةياقو اوقلت نأ مهل قبس دارفأ ىدل ةرخأتم ةيئدب تماجه روهظ
 ةجلاعلما ةيلاعفبو ةيئابولا صئاصخلاب ةيئايميكلا ةياقولا قفارت انيصقتسا دقو
 نم ةدافتسلااب ،ةطيشنلا تاروصتلما نع ةمجانلا ديدج نم ةثعبنلما ايرلاملل
.ايرلالما نع ةينطو تايطعم ةدعاق
 ةطيشنلا  تاروصتلما  نع ةمجانلا  ايرلالما  تلااح عيمج انضرعتسا  :ةقيرطلا
 دونجلا  فوفص ينب  2001و  1999  يـماع  نـيب  ةرـتفلا  يـف  تـثدح  يتلا
 يـتلا  تلااـحلا  هذـه  ددـع  نأ  اـندجوو  ،اـيرلالماب  ةباصلإا  رطخل  ينضَّرعلما
 .ةلاح 1158 غلب دق 2003 ماع نم برمسيد/لولأا نوناك 31 لـبق تـعقو
 نيرهش  لبق  عقت  يتلا  تلااحلا  اهنأب  ةركابلا  ةيئدبلا  تماجهلا  تفِّرُع  دقو
 تماجهلا تفِّرُع مايف ،ايرلالماب ةباصلإا رطخل ضرعتلل موي رخآ نم لقأ وأ
 موي رخآ نم نيرهش نم ثركأ دعب عقت يتلا تلااحلا اهنأب ةرخأتلما ةيئدبلا
.ايرلالماب ةباصلإا رطخل ضرعتلل
 634  ناـك  ،ةـلاح 1158  اـهدادعت  غـلب  يتلا  تلااحلا  ينب نم :تادوجولما
 قلتت  لم  )%28(  ةلاح  324و  ،ةـيئايميك  ةـياقو  ىـ َّقلت  دق  )%72(  ةـلاح
 اهاصقأ  تغلبو  ،فيصلا  في تلااحلا  مظعم تثدح دقو .ةيئايميك  ةجلاعم
 لىإ ةيئايميكلا ةياقولا ةصق ليلحت ىدلو .سطسغأ/بآو ويلوي/زوتم ْيَرهش في
 ةيئدبلا  تماجهلا تناكو .ةتوافتم تاقوأ في ناك اهب ءدبلا  نأ ينبت تاقبط
 تناك مايف ،ةيئايميك ةياقو قلتت لم يتلا ةعومجلما ىدل ًاعويش ثركأ ةركابلا
 ؛ةرخأتلما ةيئدبلا تماجهلا نم ةيئايميكلا ةياقولا تقلت يتلا تلااحلا مظعم
 461 ينب نم ةلاح 312 ناك ةرخأتلما ةيئدبلا تماجهلاب ينباصلما ءلاؤه نمو
 ةمجهلا  ةجلاعم  دعبو  .مظتنم  لكشب  ينكايمبرلا  اوقلتي  لم  )%67.7(  ةلاح
 ءافش ققحتو )%1.2( ةلاح 1158 ينب نم ةلاح )14( ةجلاعم تديعأ لىولأا
 مظنلاو  تاعرجلا  سفن  مادختساب  اهتجلاعم  تديعأ  يتلا  تلااحلا  عيمج
.لىولأا ةجلاعلما في تمدختسا يتلا ةيجلاعلا
 نم  ةثعبنلما  ايرلاملل  ةرخأتلما  ةيئدبلا  تماجهلا  في  دايدزا  كانه  :جاتنتسلاا
 مادختساب قفارتو ،ايروك ةيروهمج في ةطيشنلا تاروصتلما نع ةمجانلا ديدج
.ةيئايميكلا ةياقولا
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Table 4. Cases of P. vivax malaria that occurred in soldiers and veterans of 
the Republic of Korea army after the start of the second round of 
chemoprophylaxis, stratified by history of chemoprophylaxis
Chemoprophylaxis received No. of 
patients
Latency period P-valuea
First year Second year Early Late
Yes Yes 443 (100)b 220 (49.7) 223 (50.3) < 0.001
No 113 (100)  113  (100.0)  0  (0.0)
Total 556 (100) 333 (59.9) 223 (40.1)
No Yes 155 (100)  24  (15.5) 131 (84.5) < 0.001
No 252 (100) 173 (68.7)  79  (31.3)
Total 407 (100) 197 (48.4) 210 (51.6)
a  c² test.
b  Figures in parentheses are percentages.
